vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Target Price of $55.83

vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $55.83.

VTVT has been the subject of a number of analyst reports. Rodman & Renshaw started coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target for the company. BTIG Research boosted their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. HC Wainwright cut their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $31.18 on Wednesday. The company’s fifty day moving average is $32.02 and its 200 day moving average is $33.66. vTv Therapeutics has a fifty-two week low of $19.50 and a fifty-two week high of $44.00. The stock has a market capitalization of $122.82 million, a PE ratio of -29.42 and a beta of 0.21.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). As a group, research analysts forecast that vTv Therapeutics will post -2.35 earnings per share for the current year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.